SGMO vs CRSP: Sangamo vs CRISPR Therapeutics Stock Comparison: AI Score, Valuation, Performance and Upside
Sangamo is a gene editing pioneer using zinc finger nuclease technology with pharma partnerships, while CRISPR Therapeutics has achieved the world's first CRISPR therapy approval and has a more advanced clinical pipeline. CRISPR Therapeutics is the more advanced gene editing company; Sangamo's ZFN technology is older and faces competitive challenges from CRISPR-based approaches.
SGMO vs CRSP is a legacy zinc finger gene editing platform with pharma partnerships versus the CRISPR gene editing leader with an approved therapy — CRISPR Therapeutics has validated its platform with regulatory approval; Sangamo depends on clinical execution in a more competitive landscape.
SGMO and CRSP are closely matched — they split the tracked metrics evenly.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want exposure to zinc finger nuclease gene editing at a lower valuation than CRISPR companies
- believe Sangamo's pharma partnerships provide milestone income that de-risks cash burn
- are comfortable with higher clinical execution risk and a more competitive technology position
- prefer a diversified pipeline spanning hemophilia, neurology, and cell therapy at low absolute price
- want the gene editing company with the first approved CRISPR therapy validating the platform
- value Vertex partnership as commercial infrastructure that reduces CRSP's revenue uncertainty
- prefer a more advanced gene editing company with both approved products and a diversified pipeline
- are comfortable with Casgevy market adoption uncertainty in exchange for platform validation
| Metric | SGMO | CRSP |
|---|---|---|
| AI scorei | N/A | 48.7 |
| AI ranki | N/A | #743 |
| Latest closei | N/A | $49.25 |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | SGMO | CRSP |
|---|---|---|
| 1Y ago | N/A | $7.2K (-28.0%) started 2025-10-16 |
| 5Y ago | N/A | $5.12K (-48.8%) started 2021-10-18 |
| 10Y ago | N/A | $34.95K (+249.5%) started 2016-10-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | SGMO | CRSP |
|---|---|---|
| Market capi | N/A | $5.44B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | N/A | -16.10 |
| Price/Salesi | 1.47 | N/A |
| EV/Revenuei | N/A | 292.23 |
| Analyst targeti | N/A | $87.56 |
| Target upsidei | N/A | +55.54% |
| Metric | SGMO | CRSP |
|---|---|---|
| Revenue growthi | N/A | 1041.40% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | -1611.75% |
| Operating margini | N/A | -1127.55% |
| Profit margini | N/A | 0.00% |
| ROIC proxyi | N/A | -26.10% |
| Return on equityi | N/A | -26.10% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.74 | 1.74 |
| Debt/equityi | N/A | 44.87 |
| Current ratioi | N/A | 17.85 |
| Quick ratioi | N/A | 17.79 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | SGMO | CRSP |
|---|---|---|---|
| 1Y | Growthi | N/A | -28.03% |
| CAGRi | N/A | -28.04% | |
| Volatilityi | N/A | 58.17% | |
| Sharpe ratioi | N/A | -0.36 | |
| Sortino ratioi | N/A | -0.52 | |
| Max drawdowni | N/A | 40.06% | |
| Current drawdowni | N/A | 33.42% | |
| Avg drawdowni | N/A | 26.87% | |
| Ulcer Indexi | N/A | 27.64% | |
| Max daily dropi | N/A | 11.59% | |
| Max wkly dropi | N/A | 18.19% | |
| 5Y | Growthi | N/A | -48.81% |
| CAGRi | N/A | -12.55% | |
| Volatilityi | N/A | 60.95% | |
| Sharpe ratioi | N/A | 0.01 | |
| Sortino ratioi | N/A | 0.01 | |
| Max drawdowni | N/A | 68.81% | |
| Current drawdowni | N/A | 50.88% | |
| Avg drawdowni | N/A | 43.93% | |
| Ulcer Indexi | N/A | 45.40% | |
| Max daily dropi | N/A | 13.32% | |
| Max wkly dropi | N/A | 21.49% | |
| 10Y | Growthi | N/A | +249.54% |
| CAGRi | N/A | +13.34% | |
| Volatilityi | N/A | 63.96% | |
| Sharpe ratioi | N/A | 0.44 | |
| Sortino ratioi | N/A | 0.68 | |
| Max drawdowni | N/A | 85.11% | |
| Current drawdowni | N/A | 76.55% | |
| Avg drawdowni | N/A | 50.10% | |
| Ulcer Indexi | N/A | 56.56% | |
| Max daily dropi | N/A | 17.10% | |
| Max wkly dropi | N/A | 30.47% |
| Category | SGMO | CRSP |
|---|---|---|
| Company | Sangamo Therapeutics, Inc. | CRISPR Therapeutics AG |
| Sector | Healthcare | Healthcare |
| Industry | N/A | Biotechnology |
| Core business | Pioneer in zinc finger nuclease (ZFN) gene editing with a diversified pipeline in hemophilia, neurological diseases, and cell therapy. Sangamo has technology licensing partnerships with major pharma (Pfizer, Biogen, Novartis). | Gene editing company with the world's first approved CRISPR therapy (Casgevy for sickle cell disease) co-developed with Vertex Pharmaceuticals, plus pipeline programs in diabetes, oncology, and in vivo editing. |
| Investor focus | Clinical program success in hemophilia and neurological diseases, partner milestone payments, ZFN vs CRISPR competitive position, and cash runway management. | Casgevy commercial ramp, CTX112 diabetes program, CAR-T oncology pipeline, and next-generation in vivo CRISPR delivery. |
- Sangamo has 25+ years of zinc finger nuclease experience — a deep IP estate in gene editing that predates CRISPR
- Pharmaceutical partnerships (Pfizer, Biogen) provide non-dilutive funding through milestones and royalties
- Zinc finger nucleases have achieved proof-of-concept in clinical settings, validating the underlying technology
- Casgevy is the world's first approved CRISPR therapy — a major competitive and scientific milestone
- Vertex partnership provides commercial capability without full CRSP commercial infrastructure buildout
- Pipeline diversification into diabetes, oncology, and in vivo delivery provides multiple paths to value
- ZFN technology is generally considered less efficient and harder to program than CRISPR-Cas9 — competitive disadvantage in newer programs
- Multiple clinical setbacks have eroded investor confidence in Sangamo's pipeline execution
- Cash management is critical as Sangamo has faced several restructuring cycles
- Casgevy's high cost and complex treatment process limit near-term commercial scale
- Base editing and prime editing competitors (Beam, Prime Medicine) may offer improved precision
- In vivo delivery for CRISPR remains technically challenging and largely unproven in patients
Compare more than two at a time
This page is a fixed writeup on SGMO and CRSP. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside SGMO and CRSP, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.